Loading…
Pandemic and All-Hazards Preparedness Reauthorization Act of 2011
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
93pct
162d open
vs 6,662 other HR bills in the 112th — cohort avg 39d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (43)
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2016 · fourth_quarter · Health Issues
Legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drug Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · fourth_quarter · Health Issues
Legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drugs Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · third_quarter · Medical/Disease Research/Clinical Labs
BioShield Project; Biomedical Countermeasures; Biodefense Research and Development Authority; Pandemic and All-Hazards Preparedness Reauthorization (H.R. 2405 and the Public Law); H.R. 1300, the First Responder Anthrax Preparedness Act; S.2055, Medical Countermeasure Innovations Act of 2015 provision regarding priority review vouchers contracting; Companion bill to H.R. 6, 21st Century Cures Act; extended immunity from tort liability for claims of loss caused by countermeasures against diseases or other threats of public health emergencies under the Public Readiness and Emergency Preparedness Act of 2005 Pub.L.No. 109-417 (120STAT.2831); H.R. 3299, Strengthening Public Health Emergency Response Act of 2015, provisions regarding priority review vouchers contracting; S.1915 First Responder Anthrax Preparedness Act; H.R. 2577, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act of 2017, provisions relating to the Zika supplemental bill.
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2016 · third_quarter · Health Issues
Legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drug Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · third_quarter · Health Issues
Legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drugs Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
| Republican |
| NC |
2016 · second_quarter · Health Issues
Legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drug Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · second_quarter · Health Issues
Legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drugs Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · second_quarter · Medical/Disease Research/Clinical Labs
BioShield Project; Biomedical Countermeasures; Biodefense Research and Development Authority; Pandemic and All-Hazards Preparedness Reauthorization (H.R. 2405 and the Public Law); H.R. 1300, the First Responder Anthrax Preparedness Act; S.2055, Medical Countermeasure Innovations Act of 2015 provision regarding priority review vouchers contracting; Companion bill to H.R. 6, 21st Century Cures Act; extended immunity from tort liability for claims of loss caused by countermeasures against diseases or other threats of public health emergencies under the Public Readiness and Emergency Preparedness Act of 2005 Pub.L.No. 109-417 (120STAT.2831); H.R. 3299, Strengthening Public Health Emergency Response Act of 2015, provisions regarding priority review vouchers contracting; S.1915 First Responder Anthrax Preparedness Act; H.R. 2577, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act of 2017, provisions relating to the Zika supplemental bill.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2016 · first_quarter · Medical/Disease Research/Clinical Labs
BioShield Project; Biomedical Countermeasures; Biodefense Research and Development Authority; Pandemic and All-Hazards Preparedness Reauthorization (H.R. 2405 and the Public Law); H.R. 1300, the First Responder Anthrax Preparedness Act; S.2055, Medical Countermeasure Innovations Act of 2015 provision regarding priority review vouchers contracting; Companion bill to H.R. 6, 21st Century Cures Act; extended immunity from tort liability for claims of loss caused by countermeasures against diseases or other threats of public health emergencies under the Public Readiness and Emergency Preparedness Act of 2005 Pub.L.No. 109-417 (120STAT.2831); H.R. 3299, Strengthening Public Health Emergency Response Act of 2015, provisions regarding priority review vouchers contracting; S.1915 First Responder Anthrax Preparedness Act.
Client expense: Not reported · Firm income: $100,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2016 · first_quarter · Health Issues
Legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drug Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · first_quarter · Health Issues
Legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drugs Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2015 · fourth_quarter · Medical/Disease Research/Clinical Labs
BioShield Project; Biomedical Countermeasures; Biodefense Research and Development Authority; Pandemic and All-Hazards Preparedness Reauthorization (H.R. 2405 and the Public Law); H.R. 1300, the First Responder Anthrax Preparedness Act; S.2055, Medical Countermeasure Innovations Act of 2015 provision regarding priority review vouchers contracting; Companion bill to H.R. 6, 21st Century Cures Act; extended immunity from tort liability for claims of loss caused by countermeasures against diseases or other threats of public health emergencies under the Public Readiness and Emergency Preparedness Act of 2005 Pub.L.No. 109-417 (120STAT.2831); H.R. 3299, Strengthening Public Health Emergency Response Act of 2015, provisions regarding priority review vouchers contracting; S.1915 First Responder Anthrax Preparedness Act.
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2015 · fourth_quarter · Health Issues
Legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drug Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2015 · fourth_quarter · Health Issues
Legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drugs Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2015 · third_quarter · Medical/Disease Research/Clinical Labs
BioShield Project; Biomedical Countermeasures; Biodefense Research and Development Authority; Pandemic and All-Hazards Preparedness Reauthorization (H.R. 2405 and the Public Law); H.R. 1300, the First Responder Anthrax Preparedness Act; S.2055, Medical Countermeasure Innovations Act of 2015 provision regarding priorty review vouchers; Companion bill to H.R. 6, 21st Century Cures Act; extended immunity from tort liablility for claims of loss caused by countermeasures against diseases or other threats of public health emergencies under the Public Readiness and Emergency Preparedness Act of 2005 Pub.L.No. 109-417 (120STAT.2831); H.R. 3299, Strengthening Public Health Emergency Response Act of 2015, provisions regarding priority review vouchers.
Client expense: Not reported · Firm income: $50,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2015 · third_quarter · Health Issues
Legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drug Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2015 · third_quarter · Health Issues
Legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drugs Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2015 · second_quarter · Medical/Disease Research/Clinical Labs
BioShield Project; Biomedical Countermeasures; Biodefense Research and Development Authority; Pandemic and All-Hazards Preparedness Reauthorization (H.R. 2405 and the Public Law); H.R. 1300, the First Responder Anthrax Preparedness Act.
Client expense: Not reported · Firm income: $50,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2015 · second_quarter · Health Issues
Legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drug Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2015 · second_quarter · Health Issues
Legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drugs Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2015 · first_quarter · Medical/Disease Research/Clinical Labs
BioShield Project; Biomedical Countermeasures; Biodefense Research and Development Authority; Pandemic and All-Hazards Preparedness Reauthorization (H.R. 2405 and the Public Law).
Client expense: Not reported · Firm income: $70,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2015 · first_quarter · Health Issues
Legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drug Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2015 · first_quarter · Health Issues
Legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drugs Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2014 · fourth_quarter · Medical/Disease Research/Clinical Labs
BioShield Project; Biomedical Countermeasures; Biodefense Research and Development Authority; Pandemic and All-Hazards Preparedness Reauthorization (H.R. 2405 and the Public Law).
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2014 · fourth_quarter · Health Issues
Legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drugs Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2014 · fourth_quarter · Health Issues
Legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drugs Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2014 · third_quarter · Medical/Disease Research/Clinical Labs
BioShield Project; Biomedical Countermeasures; Biodefense Research and Development Authority; Pandemic and All-Hazards Preparedness Reauthorization (H.R. 2405 and the Public Law).
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2014 · third_quarter · Health Issues
Legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drugs Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2014 · third_quarter · Health Issues
Legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drugs Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2014 · second_quarter · Medical/Disease Research/Clinical Labs
BioShield Project; Biomedical Countermeasures; Biodefense Research and Development Authority; Pandemic and All-Hazards Preparedness Reauthorization (H.R. 2405 and the Public Law).
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
2014 · second_quarter · Health Issues
Legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drugs Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2014 · second_quarter · Health Issues
General health care coverage and reimbursement; implementation issues regarding H.R. 3590, the Patient Protection and Affordable Care Act; legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drugs Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $35,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2014 · second_quarter · Health Issues
Legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drugs Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2014 · first_quarter · Medical/Disease Research/Clinical Labs
BioShield Project; Biomedical Countermeasures; Biodefense Research and Development Authority; Pandemic and All-Hazards Preparedness Reauthorization (H.R. 2405 and S. 1855)
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
2014 · first_quarter · Health Issues
Legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drugs Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2014 · first_quarter · Health Issues
General health care coverage and reimbursement; implementation issues regarding H.R. 3590, the Patient Protection and Affordable Care Act; legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drugs Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $51,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2014 · first_quarter · Health Issues
Legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drugs Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2013 · second_quarter · Medical/Disease Research/Clinical Labs
BioShield Project; Biomedical Countermeasures; Biodefense Research and Development Authority; Pandemic and All-Hazards Preparedness Reauthorization (H.R. 2405 and S. 1855).
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
2013 · fourth_quarter · Health Issues
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; Food and Drug Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2013 · fourth_quarter · Medical/Disease Research/Clinical Labs
BioShield Project; Biomedical Countermeasures; Biodefense Research and Development Authority; Pandemic and All-Hazards Preparedness Reauthorization (H.R. 2405 and S. 1855)
Client expense: Not reported · Firm income: $30,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
2013 · fourth_quarter · Health Issues
Legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drugs Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2013 · fourth_quarter · Health Issues
General health care coverage and reimbursement; implementation issues regarding H.R. 3590, the Patient Protection and Affordable Care Act; legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drugs Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $51,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2013 · fourth_quarter · Health Issues
Legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drugs Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2013 · third_quarter · Health Issues
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; Food and Drug Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2013 · third_quarter · Health Issues
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; Food and Drug Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: Not reported
2013 · third_quarter · Medical/Disease Research/Clinical Labs
BioShield Project; Biomedical Countermeasures; Biodefense Research and Development Authority; Pandemic and All-Hazards Preparedness Reauthorization (H.R. 2405 and S. 1855)
Client expense: Not reported · Firm income: $50,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
2013 · third_quarter · Health Issues
General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drugs Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $25,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2013 · third_quarter · Health Issues
Legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drugs Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2013 · third_quarter · Health Issues
General health care coverage and reimbursement; implementation issues regarding H.R. 3590, the Patient Protection and Affordable Care Act; legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drugs Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $51,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2013 · third_quarter · Health Issues
Legislative and regulatory issues related to biodefense countermeasure development and procurement, including H.R. 2405, the Pandemic and All-Hazards Preparedness Act Reauthorization; and the Food and Drugs Administration legislative and regulatory issues.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE